Navigation Links
Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Date:12/21/2011

CARSON CITY, Nev., Dec. 21, 2011 /PRNewswire/ -- Denali Concrete Management Inc. (OTCBB: DCMG) announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel. The randomized, double-masked clinical trial will include 231 patients who will be randomized to receive 2 doses of CF101 and Placebo, for a period of 24 weeks.  The primary efficacy endpoint will be complete clearing of corneal staining.

The population suffering from Dry Eye Syndrome is estimated at 49 million people in the seven major markets and is characterized by eye irritation symptoms, blurred and fluctuating vision, tear film instability, increased tear osmolarity and ocular surface epithelial disease. People with Dry Eye Syndrome experience constant ocular discomfort and a decrease in visual function; in severe cases, Dry Eye Syndrome may result in deterioration of vision.

Dr. Pnina Fishman, the Company's interim CEO stated, "We are very pleased with the initiation of enrollment to the Dry Eye Syndrome phase 3 study. The positive data from the previous phase 2 study as well as the excellent safety profile of CF101 indicates the potential of this innovative oral drug for the treatment of Dry Eye Syndrome."

In addition, the Company announces today that by action of the Board of Directors and the shareholders, it has changed its name to OphthaliX Inc.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications including Dry Eye Syndrome (Phase 3), Glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis (Phase 2b) and Psoriasis (Phase 2/3).

About OphthaliX Inc (formerly Denali Concrete Management Inc).

OphthaliX Inc. (OTCBB: DCMG) is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. Denali's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

This release contains forward-looking statements regarding Denali Concrete Management, Inc.'s future plans and expected performance based on assumptions the Company believes to be reasonable.  A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company's reports filed with the SEC.  In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company's control. Denali Concrete Management, Inc. undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. 


'/>"/>
SOURCE Denali Concrete Management Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
2. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
5. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. Cellectar Expands Clinical Management Team
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
10. Lilly Receives NCQA Design Certification for Depression Care Management Program
11. Micromet Announces Changes in Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sanovas, ... technology accelerator, announced today the launch of its wholly owned ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO ... ... There ...
(Date:12/5/2016)... Dec. 5, 2016  Wellbridge Health and Gateway Health proudly ... solutions to Medicare and Medicaid plan members with specific high ... the unique needs of this group of consumers, Wellbridge combines ... philosophies to provide insight into members, daily behaviors and lifestyle. ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... BSI and Brenntag Canada ... States and Canada for distribution of their natural fruits and beverage colorants ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, President ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
(Date:12/5/2016)... , ... December 05, 2016 , ... “Life Will Never ... a supportive family and friends. “Life Will Never Be The Same” is the creation ... course in writing children's books and holds a degree in Christian religion and philosophy ...
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina Group of ... York was founded by James M. Maisel, MD and has been providing tertiary medical and ... followed a legacy of surpassing expectations amongst her peers. Growing up in a family ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ensure moisture measurements are consistently correct. However, regular performance testing is often ... TOLEDO offers a solution: SmartCal™ . This innovative test substance offers ...
Breaking Medicine News(10 mins):